Home/Filings/4/0001209191-21-002370
4//SEC Filing

Wells David R. 4

Accession 0001209191-21-002370

CIK 0001681682other

Filed

Jan 5, 7:00 PM ET

Accepted

Jan 6, 7:15 PM ET

Size

7.2 KB

Accession

0001209191-21-002370

Insider Transaction Report

Form 4
Period: 2021-01-05
Wells David R.
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2021-01-06$0.90/sh34,900$31,41080,003 total
  • Sale

    Common Stock

    2021-01-05$0.90/sh100$90114,903 total
Holdings
  • Common Stock

    (indirect: By StoryCorp Consulting)
    24,786
Footnotes (1)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020.

Issuer

ENDRA Life Sciences Inc.

CIK 0001681682

Entity typeother

Related Parties

1
  • filerCIK 0001480371

Filing Metadata

Form type
4
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 7:15 PM ET
Size
7.2 KB